Table I.
Clinicopathological characteristics of patients with breast cancer.
| Parameters | Total, n | Patients, n (%) |
|---|---|---|
| Age at diagnosis | 493 | |
| ≤51 years | 279 (56.6) | |
| >51 years | 214 (43.4) | |
| Menopausal status | 493 | |
| Pre-menopause | 268 (54.4) | |
| Post-menopause | 225 (45.6) | |
| Tumor size | 493 | |
| ≤2.0 cm | 325 (65.9) | |
| >2.0, <5.0 cm | 146 (29.6) | |
| ≥5.0 cm | 22 (4.5) | |
| Tumor type | 492 | |
| Ductal carcinoma | 455 (92.5) | |
| Lobular carcinoma | 11 (2.2) | |
| Mucinous carcinoma | 9 (1.8) | |
| Others | 17 (3.5) | |
| Histological grade | 492 | |
| G1 | 83 (16.9) | |
| G2 | 367 (74.6) | |
| G3 | 42 (8.5) | |
| TNM stage | 493 | |
| I–II | 364 (73.8) | |
| III–IV | 129 (26.2) | |
| Lymph node metastasis | 493 | |
| No | 268 (54.4) | |
| Yes | 225 (45.6) | |
| p53 | 397 | |
| Negative | 166 (41.8) | |
| Positive | 231 (58.2) | |
| BRCA1 | 396 | |
| Negative | 102 (25.8) | |
| Positive | 294 (74.2) | |
| Chemotherapy regimen | 386 | |
| CAF/CEF | 291 (75.4) | |
| CAF/CEF+T | 95 (24.6) |
CAF/CEF, cyclophosphamide/doxorubicin or epirubicin/5-fluorouracil; CAF/CEF + T, CAF/CEF+ docetaxel; TNM, tumor-node-metastasis; BRCA1, breast cancer susceptibility gene 1.